Профиль Infant Bacterial Therapeutics AB (B)
Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. Its product include IBP-9414 and IBP-1016. The IBP-9414, is a drug candidate contains Lactobacillus reuteri which is a human bacterial strain naturally present in breast milk that improves feeding tolerance in premature infants and IBP-1016, helps in treating gastroschisis, a severe birth defect in infants. The company was founded in 2013 and is headquartered in Stockholm, Sweden.